GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer
Josefine Sandström(Linköping University), Olle Stål(Linköping University)
Cited by 8
Related Papers
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
|British Journal of Cancer|2002|393
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
|Breast Cancer Research and Treatment|2012|99
Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
|Clinical Cancer Research|2010|58
S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts
|Endocrine Related Cancer|2015|34
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
|Breast Cancer Research|2010|34